Target Lesion Failure With Current Drug-Eluting Stents: Evidence From a Comprehensive Network Meta-Analysis.

Abstract

The aim of this study was to investigate the efficacy and safety of currently used drug-eluting stents (DES). Head-to-head comparisons among newer DES have shown conflicting results. For this network meta-analysis, randomized controlled trials comparing different types of currently used DES were searched in PubMed, Scopus, and proceedings of international meetings. The primary endpoint was target lesion failure (TLF) at 1 year and at long-term follow-up. Seventy-seven trials with 99,039 patients were selected for this network meta-analysis. Among the 10 DES included in the meta-analysis, 4 received the most extensive investigation: Orsiro, XIENCE, Nobori/BioMatrix, and Resolute. At 1 year, the Orsiro stent was associated with lower rates of TLF compared with XIENCE (odds ratio [OR]: 0.84; 95% confidence interval [CI]: 0.71 to 0.98; p=0.03), Resolute (OR: 0.81; 95%CI: 0.68 to 0.95; p=0.01), and Nobori/BioMatrix (OR: 0.81; 95%CI: 0.67 to 0.98; p=0.03). Orsiro had the highest probability to be the best (70.8%), with a surface under the cumulative ranking curve value of 95.9%. However, after a median follow-up period of 50months (range: 24 to 60months), no significant difference was apparent in the rates of TLF between any DES, although Orsiro still ranked as the best stent (58.6% probability to be the best). In addition, Orsiro had a lower rate of long-term definite stent thrombosis compared with Nobori/BioMatrix (OR: 0.60; 95%CI: 0.36 to 0.98; p=0.04) and lower rates of definite and probable stent thrombosis compared with Resolute (OR: 0.66; 95%CI: 0.45 to 0.99; p=0.04). No differences in cardiac mortality between any DES were observed. Orsiro is associated with a lower 1-year rate of TLF compared with XIENCE, Resolute, and Nobori/BioMatrix but with an attenuation of the efficacy signal at long-term follow-up.